Menard Financial Group LLC Boosts Stake in Novo Nordisk A/S (NYSE:NVO)

Menard Financial Group LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 12,283 shares of the company’s stock after acquiring an additional 102 shares during the quarter. Novo Nordisk A/S comprises 1.0% of Menard Financial Group LLC’s holdings, making the stock its 21st biggest position. Menard Financial Group LLC’s holdings in Novo Nordisk A/S were worth $1,463,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. 1620 Investment Advisors Inc. purchased a new position in Novo Nordisk A/S in the second quarter worth $25,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S in the third quarter valued at about $28,000. Finally, Abound Wealth Management lifted its position in shares of Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after acquiring an additional 157 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.5 %

Shares of NYSE NVO opened at $109.16 on Wednesday. The firm has a market cap of $489.86 billion, a P/E ratio of 35.33, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The firm’s 50 day moving average price is $112.18 and its 200 day moving average price is $127.59.

Analyst Ratings Changes

A number of brokerages have issued reports on NVO. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets lowered their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.